- Home
- RLMD vs MIRA Comparison
RLMD vs MIRA Comparison
Compare RLMD & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- MIRA
- Stock Information
- Founded
- RLMD 2004
- MIRA 2020
- Country
- RLMD United States
- MIRA United States
- Employees
- RLMD N/A
- MIRA N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- MIRA Health Care
- Exchange
- RLMD Nasdaq
- MIRA Nasdaq
- Market Cap
- RLMD 22.0M
- MIRA 19.5M
- IPO Year
- RLMD N/A
- MIRA 2023
- Fundamental
- Price
- RLMD $0.67
- MIRA $1.25
- Analyst Decision
- RLMD Buy
- MIRA Strong Buy
- Analyst Count
- RLMD 3
- MIRA 2
- Target Price
- RLMD $5.00
- MIRA $14.00
- AVG Volume (30 Days)
- RLMD 478.7K
- MIRA 175.1K
- Earning Date
- RLMD 08-06-2025
- MIRA 08-12-2025
- Dividend Yield
- RLMD N/A
- MIRA N/A
- EPS Growth
- RLMD N/A
- MIRA N/A
- EPS
- RLMD N/A
- MIRA N/A
- Revenue
- RLMD N/A
- MIRA N/A
- Revenue This Year
- RLMD N/A
- MIRA N/A
- Revenue Next Year
- RLMD N/A
- MIRA N/A
- P/E Ratio
- RLMD N/A
- MIRA N/A
- Revenue Growth
- RLMD N/A
- MIRA N/A
- 52 Week Low
- RLMD $0.24
- MIRA $0.51
- 52 Week High
- RLMD $4.47
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- RLMD 52.84
- MIRA 46.62
- Support Level
- RLMD $0.67
- MIRA $1.15
- Resistance Level
- RLMD $0.72
- MIRA $1.30
- Average True Range (ATR)
- RLMD 0.08
- MIRA 0.08
- MACD
- RLMD -0.03
- MIRA -0.01
- Stochastic Oscillator
- RLMD 40.29
- MIRA 21.43
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.